IP Library › Assignment 071275/0866
Patent Assignment
Reel/Frame 071275/0866

Security Interest

Recorded: 2025-05-14 Pages: 37
Assignor
Assignee
LSI FINANCING LLC
C/O BLUE OWL CAPITAL CORPORATION, 399 PARK AVENUE, 37TH FLOOR, NEW YORK, NEW YORK, 07677
Covered Properties (18)
Formulations of Bendamustine
Patent: 9,034,908 →
Application: 13/838,090 →
Publication: US 2013/0253025
Method of Treating Bendamustine-Responsive Conditions in Patients Requiring Reduced Volumes for Administration
Patent: 9,000,021 →
Application: 13/838,267 →
Publication: US 2013/0253026
Formulations of Bendamustine
Patent: 9,265,831 →
Application: 14/031,879 →
Publication: US 2014/0024691
Formulations of Bendamustine
Patent: 9,144,568 →
Application: 14/714,578 →
Publication: US 2015/0250766
Method of Treating Bendamustine-Responsive Conditions in Patients Requiring Reduced Volumes for Administration
Patent: 9,579,384 →
Application: 14/820,291 →
Publication: US 2015/0343061
Formulations of Bendamustine
Patent: 9,597,397 →
Application: 14/857,064 →
Publication: US 2016/0000759
Formulations of Bendamustine
Patent: 9,597,398 →
Application: 15/008,819 →
Publication: US 2016/0144034
Formulations of Bendamustine
Patent: 9,597,399 →
Application: 15/008,827 →
Publication: US 2016/0144035
Formulations of Bendamustine
Patent: 9,572,796 →
Application: 15/013,424 →
Publication: US 2016/0143887
Formulations of Bendamustine
Patent: 9,572,797 →
Application: 15/013,436 →
Publication: US 2016/0143888
Formulations of Bendamustine
Patent: 9,572,887 →
Application: 15/184,464 →
Publication: US 2016/0296621
Formulations of Bendamustine
Patent: 9,572,888 →
Application: 15/184,488 →
Publication: US 2016/0296622
Formulations of Bendamustine
Application: 15/432,335 →
Publication: US 2018/0000789
Formulations of Bendamustine
Application: 15/432,378 →
Publication: US 2018/0000938
Formulations of Bendamustine
Application: 16/509,920 →
Publication: US 2019/0350904
Formulations of Bendamustine
Application: 18/081,238 →
Publication: US 2023/0115164
Formulations of Bendamustine
Application: 18/081,251 →
Publication: US 2023/0115693
Formulations of Bendamustine
Application: 18/646,171 →
Publication: US 2024/0293372
Related Assignments (12)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Apr 30, 2014
From: SUNDARAM, SRIKANTH; TARRIFF, SCOTT L.
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 032791/0091 →
Assignment of Assignor's Interest Apr 30, 2014
From: SUNDARAM, SRIKANTH
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 032791/0599 →
Assignment of Assignor's Interest Apr 30, 2014
From: PALEPU, NAGESH R.; BUXTON, PHILIP CHRISTOPHER
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 032790/0596 →
Assignment of Assignor's Interest Feb 25, 2015
From: TARRIFF, SCOTT L.
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 035025/0435 →
License May 22, 2015
From: EAGLE PHARMACEUTICALS, INC.
To: CEPHALON, INC.
Reel/Frame 035696/0856 →
License Jun 23, 2015
From: EAGLE PHARMACEUTICALS, INC.
To: CEPHALON, INC.
Reel/Frame 035887/0475 →
Security Interest Jan 26, 2017
From: EAGLE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 041095/0554 →
Security Interest Aug 21, 2017
From: EAGLE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 043346/0871 →
Security Interest Oct 24, 2022
From: EAGLE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 061513/0804 →
Security Interest Oct 11, 2024
From: EAGLE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 068873/0898 →
Release of Security Interest Apr 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 070703/0524 →
Grant of Security Interest Feb 18, 2026
From: EAGLE PHARMACEUTICALS, INC
To: ANKURA TRUST COMPANY, LLC.
Reel/Frame 074849/0457 →